Welcome to the Staley Lab!

Staley lab space

Microbiome Analytics

The gut microbiota, characterized as the microbiome, plays a pivotal role in human health, function, and disease. Our primary research focus is to characterize patterns in microbiome imbalance, called dysbioses, that affect the onset and progression of diseases. We use next-generation sequencing, metagenomics approaches, ecological principles, and translational mouse models to fully understand shifts in microbial community composition, organization, and function in the hopes of developing personalized, microbiota-based therapeutics and practices. Current areas of study include:

1. Determining the role of the microbiome in the onset and progression of obesity.

2. Characterizing shifts in gut microbiota related to intestinal damage during chemotherapy for acute leukemia and bone marrow transplant.

3. Evaluating the microbiome-tumor interactions in colorectal cancers.

4. Developing encapsulated microbial preparations to treat recurrent Clostridium difficile infections and other conditions.

Lab news

February 14, 2020 - Our website has moved to a new format. We will be posting updates here from now on.

January 24, 2020 - Danielle Maeser's page updated.

January 4, 2020 - Our paper Microbiome swings with repeated insults was accepted in the British Journal of Haematology.

December 16, 2019 - Our paper Levaquin gets a pass was accepted in Biology of Blood and Cancer.

December 9, 2019 - We received the BRAINS award from the Medical School with co-PI Eugenia Shmidt to study the role of the microbiome and inflammation in infertility.

December 2, 2019 - Our paper An alpha-defensin gene single nucleotide polymorphism modulates the gut microbiota and may alter the risk of acute graft-versus-host disease was accepted in the British Journal of Haematology